This distinct mechanism sets benralizumab apart from other anti-IL-5 agents, enabling effective eosinophil depletion and suppression of eosinophilic inflammation, a response clearly observed in our case through the rapid and sustained resolution of both eosinophilia and clinical manifestations [41]. Here, IL5 is linked to Increased total eosinophil count.